-

Thermo Fisher Scientific Elects New Director to Board

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced Ruby Chandy has been elected to its board of directors, effective March 1, 2022. Ms. Chandy’s appointment will bring the total number of Thermo Fisher board members to 13.

Ms. Chandy was the president of the Industrial Division of Pall Corporation, a leading supplier of filtration, separation, and purification technologies. Previously, Ms. Chandy was chief marketing officer at the Dow Chemical Company and Rohm and Haas Corporation.

Ms. Chandy currently serves on the board of directors of DuPont de Nemours, Inc. (NYSE:DD) and Flowserve Corporation (NYSE: FLS). She also serves on the Advisory Board of Pritzker Private Capital, the MIT Sloan Americas Executive Board and is a mentor-in-residence at the University of Pennsylvania Penn Center for Innovation (PCI).

“I am pleased to welcome Ruby to the Thermo Fisher board and look forward to her insights gained through management positions across several industries,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “Her experience will provide an important perspective as we work every day to fulfill our Mission of enabling our customers to make the world healthier, cleaner and safer.”

Ms. Chandy received a master’s degree in management from the MIT Sloan School, a master’s degree in materials science and engineering from Northwestern University and a bachelor’s degree in materials science and engineering from MIT.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact Information:
Ron O’Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

Thermo Fisher Scientific Inc.

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact Information:
Ron O’Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

More News From Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Launches First Orbitrap Mass Spectrometers for Isotope Ratio Analysis, Enabling More Labs to Decode the Story Behind a Sample

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today introduced the Thermo Scientific™ Orbitrap™ Isora™ Mass Spectrometer and Orbitrap Isora Pro Mass Spectrometer, the company’s first Orbitrap instruments with a dedicated isotope ratio analysis mode. Together with the Thermo Scientific™ Vanquish™ Duo UHPLC System and new Isotope Discoverer™ Software, the instruments form an integrated workflow designed to make molecular-level isotope ratio analys...

Thermo Fisher Scientific Completes Sale of its Microbiology Business to Astorg

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed the sale of its microbiology business to Astorg, a leading pan-European private equity firm, for consideration of approximately $1.075 billion, consisting of cash and a $50 million seller note. The microbiology business provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food safety testing....

Thermo Fisher Scientific Collaborates with The Michael J. Fox Foundation to Advance Proteomics-Enabled Parkinson’s Precision Medicine

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the completion of Olink Explore HT proteomic analysis of approximately 5,500 research samples from The Michael J. Fox Foundation’s (MJFF) landmark study, the Parkinson’s Precision Medicine Initiative (PPMI). The resulting data are now in PPMI’s data repository, where they are available to the global research community. The project creates a large-scale proteomics resource designe...
Back to Newsroom